Market Overview

GlaxoSmithKline and J&J's HIV Drug Juluca Received Approval In Japan

Share:
Related JNJ
Fed Meeting Starts With Market Off To Worst December Start in 38 Years
Johnson & Johnson CEO Tells Cramer 'Thousands Of Studies' Refute Asbestos Allegations
Johnson & Johnson: Caution Here (Seeking Alpha)
Related GSK
Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate
Jim Cramer Gives His Opinion On GlaxoSmithKline, Abbott Laboratories And More
Epizyme earns $8M milestone payment for initiation of clinical development for PRMT1 inhibitor (Seeking Alpha)

GlaxoSmithKline plc (NYSE: GSK) and partner Johnson & Johnson (NYSE: JNJ) announced that Japan's Ministry of Health, Labour and Welfare granted a marketing approval to Juluca for the maintenance treatment of HIV -1 infection.

Juluca combines two approved HIV drugs — Tivicay (50 mg) and Edurant (25 mg) — into a single, once-daily pill for the treatment of virologically suppressed HIV-1 infection.

Tivicay, a novel investigational integrase strand transfer inhibitor (INSTI), is marketed by ViiV Healthcare, an HIV company majorly owned by Glaxo and Pfizer Inc. (NYSE: PFE). Edurant is a non-nucleoside reverse transcriptase inhibitor (NNRTI) marketed by Janssen, J&J's pharma arm. Juluca has been developed under a partnership between ViiV Healthcare and Janssen.

Related Links:

9 Policy Catalysts For Health Care Investors To Watch Before Year's End

The Health Care Stocks With A Lot Riding On The Midterm Elections

The preceding article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.

Posted-In: contributor contributorsNews FDA

 

Related Articles (GSK + JNJ)

View Comments and Join the Discussion!

Trump Threatens To Cut GM's Subsidies

Survey: Smartphones Fuel Record Cyber Monday Sales